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ABSTRAK 
 
Pengenalan dan Objektif : Kanser neuroendokrin berpunca dari sistem sel 
neuroendokrin yang berada di semua organ di dalam badan manusia dan mempunyai 
pelbagai simptom, lokasi asal dan tahap agresif yg berbeza. Kanser neuroendokrin yg 
berasal dari sistem pencernaan dan pankreas (GEPNET) semakin mendapat perhatian 
berikutan simptom yang tidak spesifik,  kekeliruan dalam sistem penamaan, pengredan 
dan pengenalan klasifikasi WHO 2010. Survivin adalah “inhibitor apoptosis’ yang secara 
khusus hanya diekspresi di dalam sel-sel kanser dan bukan di sel-sel biasa. Kajian ini 
direka untuk melihat karakter klinikal dan patologi GEPNET, insiden GEPNET di 
HUSM dan nilai prognosa survivin di dalam GEPNET. 
 
Metodologi : Kajian ‘ cross sectional’ ini dijalankan ke atas semua kes-kes GEPNET dari 
tahun 1998 hingga 2016 di Hospital Universiti Sains Malaysia. Parameter klinikal and 
patologikal  dan kiraan mitosis di catat. Blok-blok tisu parafin ini kemudiannya dilabel 
secara immunohistokimia dengan survivin dan Ki67. Berdasarkan kiraan mitosis dan 
Ki67, kes-kes ini telah dibahagi mengikut gred menggunakan klasifikasi WHO 2010.  
 
Keputusan : 20 kes telah dikenalpasti. Terdapat sedikit peningkatan insiden GEPNET di 
HUSM. Kesemua kes ini mengalami simptom sakit perut. Simptom tidak spesifik lain 
yang dialami adalah perubahan dalam pola penyahtinjaan dan pendarahan dari dubur. 
Lebih separuh mengalami kurang selera makan dan berat badan (n=16). Kebanyakan 
GEPNET berasal dari sistem pencernaan (n=18) dan hanya 10% (n=2) berasal dari 
pankreas. 65% (n=13) mengalami rebakan kanser ke organ lain. Hanya 40% daripada kes 
kes ini telah diklasifikasikan mengikut WHO 2010 semenjak pengenalan klasifikasi ini 
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dan serum ‘Chromogranin A’ telah diuji pada 35% kes-kes ini. Kaedah pemeriksaan yang 
paling kerap digunakan untuk mengdiagnosa GEPNET adalah imbasan CT(n=16) diikuti 
endoskopi ( n=10) dan ultrasound (n=6).  60% kes kes di HUSM didapati tergolong dalam 
gred 3, 15% gred 2 dan 25% gred 1 mengikut klasifikasi WHO 2010. Terdapat hubungan 
yang signifikan antara rebakan sel-sel kanser dan gred mengikut WHO 2010. Tiada 
hubungan signifikan antara ekspresi survivin dan gred GEPNET. 
 
Kesimpulan: Penyelidikan ini menunjukkan terdapat peningkatan insiden GEPNET di 
HUSM dengan simptom-simptom yang tidak khusus. Tiada hubungan signifikan antara 
ekspresi survivin dan Gred mengikut klassifikasi WHO 2010. Kekurangan pangkalan 
data dan kesedaran mengenai GEPNET merupakan halangan utama dalam diagnosa dan 
pengendalian kes-kes ini.  
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ABSTRACT 
 
Background and objective :  Neuroendocrine tumours originate from the peripheral 
neuroendocrine cell system dispersed in all organs and is  heterogenous in its 
presentation, localization and aggressiveness. Those arising from the gastrointestinal tract 
and pancreas are of interest due to its increase in incidence. The introduction  of WHO 
2010 classification for these tumours abates confusion on its nomenclature which depicts 
malignant behaviour . Survivin is an apoptosis inhibitor which are specifically expressed 
in tumour cells and not in normal cells. In this study we determine the clinicopathological 
characteristics of gastroenteropancreatic neuroendocrine tumour (GEPNET), the 
incidence in HUSM and the prognostic value of survivin in this tumour entity. 
 
Materials and methods: This cross-sectional study was carried out on all cases of 
GEPNET from 1998 to 2016 in Hospital Universiti Sains Malaysia (USM). Data on the 
clinicopathological characteristics and mitoses counts were noted. We performed 
immunohistochemical staining for survivin and Ki67 in paraffin fixed paraffin embedded 
blocks. Gradings according to WHO 2010 classification were done based on Ki67 
proliferation index and mitoses. 
 
Results: Twenty cases of GEPNET were included in this study. There is a slight increase 
in GEPNET incidence in HUSM. All GEPNET presented with abdominal pain. Other 
vague symptoms include altered bowel habit and blood per rectum. More than half had 
constitutional symptoms (n=16). Majority of GEPNET arises from the gastrointestinal 
(n=18) and only 10% from the pancreas (n=2). 65% (n=13) demonstrated metastases. 
Only 40% of the cases were graded according to WHO 2010 classification since its 
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introduction. 35% had serum Chromogranin A done. The commonest investigation 
modality is CT scan (n=16) followed by endoscopy (n=10) and ultrasound (n=6). 
According to the WHO 2010 classification, 60% of the GEPNET diagnosed were in 
Grade 3 , 15% in Grade 2 and 25% in Grade 1. There was a significant association 
between occurrence of metastases and gradings of GEPNET (p=0.001).  There was no 
association between the expression of survivin and the grades in GEPNET. 
 
Conclusion: These results indicate there is an increasing trend in GEPNET incidences 
with variable vague presentations. There was no association found between the 
expression of survivin and the grades in GEPNET according to the WHO classification. 
Lack of database and awareness of the GEPNET and its latest classification is still a major 
hindrance in the diagnosis and management of the disease. 
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CHAPTER ONE : INTRODUCTION 
 
Neuroendocrine tumours, NETs are relatively rare and highly malignant 
neoplasm (Diakatou et al.). According to the US surveillance Epidemiology and End 
Result (SEER), the incidence of NET worldwide is 1 in 1000 malignancies. However in 
recent large scale studies done by Yao et al. (2013) and Ellis et al. (2010), it is believed 
that there was an increase of incidences reported compared to what was believed in 
previous studies. This increase in both studies are said to be contributed by improvement 
in diagnostic techniques and increased survival span. 
The term “karzinoide” was introduced by Oberndorfer in 1907, where he 
described six cases of the small intestine (Klöppel, October 2007). This term which 
means carcinoma-like implied that these tumours are benign, thus creating a lot of 
confusion of the nature of the disease. However, over the years, more and more 
understandings were discovered on the endocrine nature of the disease (Klöppel, October 
2007) and it is now agreed that this tumour has a malignant potential. 
The tumour constitutes a heterogenous group of neoplasm that may arise in 
virtually every topographic localization in the body (Pasaoglu et al., 2015). They 
originate from the peripheral neuroendocrine cell system dispersed in all organs (Emma 
Elizabeth Ilett, 2015). Those arising from the gastrointestinal and pancreatic system are 
collectively known as gastroenteropancreatic neuroendocrine tumour or GEPNET in 
short. More than a dozen neuroendocrine cell types have been described in the human 
(Hofsli, 2006) and they share common morphological, biochemical and ultrastructural 
features.  The neuroendocrine cells are capable of producing a variety of hormones and 
neuropeptides (neurotransmitters and growth factors). 
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Patients with GEPNET present with wide variety of clinical presentation. 
GEPNET can be divided into the functioning and non-functioning. The non-functioning 
group are not associated with symptoms and signs of hormone secretion. The functioning 
unit, is described as such, because they exhibit symptoms which are associated with the 
hormones and neuropeptides produced (Uccella et al., 2015). For example, insulin 
produced in neuroendocrine tumour in pancreas ( Insulinoma) causes hypoglycaemia and 
gastrin produced in gastrinoma may lead to Zollinger- Ellison syndrome Similarly 
serotonin secretion by intestinal and more rarely pancreatic NET lead to carcinoid 
syndrome (Raphael MJ, 2017) and many more different hormones. Thus, the occurrences 
of this disease are either discovered incidentally or by the non-specific symptoms related 
to the production of these hormones. This situation poses difficulty for clinicians to 
establish the diagnosis of neuroendocrine tumour and instead they may arrive at a 
different diagnosis.  
The diagnoses of neuroendocrine tumour requires an integrated and 
multidisciplinary approach which includes medical oncologist, surgeons, radiologist and 
pathologist (Raphael MJ, 2017). There are many modalities utilized for the diagnosis of 
GEPNET which encompasses clinical evaluations, radio imaging, biochemical tests, 
morphological and immunohistochemical markers in attempt to identify the origin of the 
neuroendocrine tumours.  
Plasma Chromogranin A is a reliable diagnostic and prognostic biomarker 
(Massironi et al., 2015). It shows high sensitivity and specificity rate among Asian 
population (Chou et al., 2012). Excess serotonin levels in serotonin producing NET can 
be measured via 24-hour urine 5-HIAA that has been excreted (Özaslan et al., 2014). 
Histological recognition also plays an important role in the diagnosis of GEPNET, which 
3 
 
includes morphological and immunohistochemical staining. Most neuroendocrine 
tumours show reactivity to either synaptophysin or chromogranin A 
immunohistochemical tissue marker regardless of its histological subtypes (Kimiloglu 
Sahan et al., 2015). Diagnostic imaging modalities used for the diagnosis of GEPNET 
include standard CT or MRI and functional imaging, which exploit the overexpression of 
somatostatin receptor seen in neuroendocrine tumour. Radiolabelled somatostatin 
analogues injected in the blood stream can bind to the tumour cells to help localized the 
tumour (Raphael MJ, 2017). 
The grading and classification has gone through tremendous changes over the 
decades.  This is with the realization of the importance of these gradings in predicting 
prognosis and outcome (Lee et al., 2014). In 2000, the World Health Organization 
introduced its classification of GEPNET by integrating the concepts of tumour 
heterogeneity, tumour differentiation and malignancy (Hamilton SR, 2000). However, 
current recommendation is based on an updated WHO classification which was upgraded 
in 2010 where there are usage of a more well defined and meticulous classification 
(Bosman, 2010). In this new classification, Ki67 proliferation index and mitosis counts 
are the key indicator in determining the grades of GEPNET. Ki67 has been suggested as 
one of the reliable and reproducible indicator of malignant behaviour in GEPNET tumour 
and has the ability to discriminate between a less aggressive and a more aggressive 
tumour (Khan et al., 2013; Miller et al., 2014; Salama et al., 2014). 
There is an increasing interest in the utility of survivin as a diagnostic and 
prognostic marker in GEPNET. Survivin is a protein belonging to the family of apoptosis 
inhibitor. It suppresses apoptosis and regulates cell division (Altieri, 2008).The 
expression of survivin is said to be tumour specific (Velculescu et al., 1999). Many 
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studies also showed that survivin is a novel prognostic factor especially in well 
differentiated tumour. This study will investigate the expression of survivin in GEPNET. 
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CHAPTER TWO : LITERATURE REVIEW 
 
 
2.1 CLINICOPATHOLOGICAL PRESENTATION 
 
 Neuroendocrine tumours have always been regarded as a rare malignancy. 
However, there are more and more studies done on neuroendocrine tumour and being the 
highlights of many medical discussions proving that neuroendocrine tumour is not as rare 
as thought before. A large study by (Yao et al., 2008) showed a significant increase in 
incidence and prevalence. However, most of these studies were done among Caucasian 
population which may not reflect the real situation in Malaysia. To date, there has been 
only one study done in Malaysia, describing the clinicopathology, diagnoses and 
management of GEPNET done (Gunavathy, 2014) 
Neuroendocrine tumour consists of a spectrum of malignancies that can arise from 
neuroendocrine cells that exist in any parts of the body. These tumours are most 
commonly found located in the gastrointestinal tract than in the pancreas (de Miguel 
Novoa et al., 2014; Pasaoglu et al., 2015). However, study done in Malaysia  by 
Gunavathy (2014)   showed that 67.2% of the primary site of tumour originated from the 
pancreas. Again, this highlights the importance of initiating a local registry as our 
clinicopathological pattern may differ from other regions. 
 There are as many as 15 types of neuroendocrine cells in the pancreas and 
gastrointestinal tracts and each are capable of producing  peptides that causes certain 
hormonal syndrome (Rindi, 1999). These cells share a number of antigens with nerve 
elements, thus, the term ‘ neuroendocrine’ was adopted (Rindi, 2000). Among the 
peptides discovered are insulin, serotonin, gastrin, histamine and others in different 
locations and concentrations along the gastrointestinal tract and pancreas as shown in 
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Table 2.1 (Solcia and Vanoli, 2014). Those capable of producing the different hormonal 
symptoms are regarded as functioning type causing hyperfunctional syndromes or 
secretory symptoms such as hypoglycaemia, diabetes mellitus and acid hypersecretion  
and carcinoid syndrome as described by de Miguel Novoa et al. (2014). In such cases, 
the tumour itself is labelled according to its associated hyperfunctional syndromes such 
as insulinoma, gastrinoma etc (Rindi et al., 1998). Brzozowska et al. (2009) also 
documented a rare case of hypercalcaemia from excessive secretion of parathyroid 
hormone-related protein (PTHrP) in a lady with advanced GEPNET who had evidence 
of osteoporosis on bone mineral density scan. 
Carcinoid syndrome encompasses another different sets of syndrome which 
includes vasomotor symptoms such as flushing, hypertension or hypotension, 
gastrointestinal hypermotility such as diarrhoea, right sided cardiac involvement, 
bronchospasm, pelagra, hepatomegaly, proximal myopathy and others (Melnyk, June 
1997) . These constellation of symptoms is due to the secretion of serotonin, tachykinins, 
prostaglandins, catecholamines and histamines to varying extent in which serotonin is 
very prominent (de Herder, 2007). 
To make things more complicated, it is unclear as why some of these cells do not 
have the propensity to develop into tumour especially those involving the upper intestine 
cells like secretin and cholecystokinin, while tumours like gastrinoma which is expected 
to develop in the gastric can occur in the pancreas (Solcia and Vanoli, 2014). The 
unpredictable behaviour of these functioning neuroendocrine cells leads to variability in 
the presenting symptoms resulting in the late management of the patient.  
However, not all cases of GEPNET produces hormones, these we regard as non-
functioning. Patients with non-functioning GEPNET mostly manifest with abdominal 
7 
 
symptoms such as abdominal pain, diarrhoea, constipation, abdominal pain, GI bleeding, 
jaundice, vomiting and constitutional symptoms such as anorexia and weight loss (de 
Miguel Novoa et al., 2014). Abdominal symptoms are more frequently found in GEPNET 
patients in comparison to hyperfunctional syndromes (Niederle and Niederle, 2011; 
Birnbaum et al., 2014). 
Table 2.1: Different peptides and its concentration along the gastrointestinal tracts and 
pancreas 
*Adapted from Solcia and Vanoli (2014) 
 
Such vast array of clinical symptoms which can be very nonspecific lead to 
delayed presentation and detection. Approximately 70% of patients who were diagnosed 
with GEPNET were found to have lymph node involvement and distant metastases in a 
study conducted by (Niederle et al., 2010). Delayed presentation, delayed diagnosis, 
inadequate hormonal, biochemical and histopathological examination and the lack of 
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multidisciplinary approach (Gunavathy, 2014) causes inefficiency in the management of 
these patient.  
 
2.2 WHO CLASSIFICATION 
 
 The grading and classification of neuroendocrine tumour is imperative in 
predicting the prognosis and determining the treatment options. This classification allows 
for a more structured process in diagnosing and thus allowing the clinicians and 
pathologist to speak in similar language in terms of neuroendocrine tumour. 
 The grading system that we use currently has undergone a massive and significant 
evolution. The first attempt to classify GEPNET was made in 1963 by Williams and 
Sandler where they divided these tumours according to their embryological origins: the 
foregut, midgut and the hindgut. However, this classification was not useful in  clinical 
practice because of the diverse clinical behaviour (Kloppel, 2011). In 1980s and 1990s, 
the term ‘carcinoid’ and its largely incorrect benign implication, was widely employed 
for these neuroendocrine tumours (Rindi et al., 2010). 
 In 2000, WHO emerged with a more practical classification and  accepted the 
nomenclature of GEPNET and allowed the prognostic stratification of these neoplasm 
(Pasaoglu et al., 2015). GEPNETS were classified as well differentiated and poorly 
differentiated. The well differentiated category constitutes benign, uncertain behaviour 
and carcinoma. Tumour size, depth of invasion, functionality and metastases were 
considered in the WHO 2000 classification (Solcia, 2000; Heitz, 2004). Apart from the 
well differentiated and the poorly differentiated, another group known as mixed exocrine-
endocrine carcinoma was also introduced. However, the scheme was not widely 
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acknowledged. The reasons being 1) the inclusion of stage related information in the 
grading system; 2) complicated clinical-pathological classification scheme; and 3) the 
category of ‘uncertain behaviour’(Rindi et al., 2010). Furthermore, the usage of the term 
‘carcinoid’ and its incorrect benign impression impeded the universal acceptance of the 
WHO 2000 classification. 
To avoid these confusions, WHO endorsed a new classification in 2010 and 
recommended the term neuroendocrine tumours to be used generically to indicate the 
expression of neural marker in neoplastic cells, regardless of the origin. This new 
classification acknowledges the malignant potential of  neuroendocrine tumour and this 
knowledge is used to organize the classification (Rindi et al., 2010). The new WHO 2010 
classification of GEPNET retains the concept of well differentiated and poorly 
differentiated tumours. The well-differentiated neuroendocrine neoplasm were graded as 
Grade I ( mitotic count<2/10HPF and/or Ki67 index ≤2%) and Grade II ( mitotic count 
2-20/10HPFand or Ki67 index 3%-20%) All poorly differentiated tumours were termed 
neuroendocrine carcinomas and were graded as Grade 3 ( mitotic count >20/10hpf and 
or Ki67 index>20%) as illustrated in Table 2.2 (Rindi et al., 2010). The diagnosis of 
mixed neuroendocrine carcinoma (MANEC) was used when adenomatous or 
neuroendocrine components were malignant and at least 30% of each component can be 
identified. This classification is generally based on the mitotic count and Ki67 
proliferation index. The usage of stage related information and clinic-pathological 
association were omitted thus creating clear and straightforward classification. WHO 
2010 classification is said to be simple, easy to use and a repeatable classification 
(Pasaoglu et al., 2015). 
In view of the eminent qualities of the WHO 2010 GEPNET classification, it 
would be substantial if everyone could employ this classification in their daily practices. 
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This research uses the WHO 2010 GEPNET classification as it is the latest and only 
classification available.  
 
Table 2.2 : WHO 2010 Gastroenteropancreatic Neuroendocrine tumour classification 
 GRADE MITOTIC COUNT Ki-67 index 
Neuroendocrine tumour 
/carcinoid 
G1 <2 ≤ 2% 
Neuroendocrine tumour G2 2-20 3-20% 
Neuroendocrine carcinoma G3 >20 >20% 
MANEC (mixed 
adenoneuroendocrine 
carcinoma) 
When adenomatous or neuroendocrine components were 
malignant and at least 30% of each component could be 
identified 
*Adapted from (Rindi et al., 2010) 
 
Ki67 was first identified in 1991. It is a protein antigen of 345 and 395 kDa found 
on the long arm of chromosome 10 in which it’s expression is tightly related to the cell 
cycle (Gerdes et al., 1983; Gerdes et al., 1984; Gerdes et al., 1991). More precisely, Ki67 
was said to be expressed in the nucleus of proliferating G1 phase in the cell cycle, 
increases during the subsequent phases of the cell cycle and rapidly diminishes after 
mitosis (Gerdes et al., 1984; Bruno and Darzynkiewicz, 1992) and absent in the dormant 
cells (Singh et al., 2014).This knowledge of  this special characteristic can be utilize to 
employ Ki67 as a marker of cell proliferation in histological material (Scott et al., 1991) 
This protein antigen may also provide prognostic information in a range of other tumours 
as seen in lymphoma by Hall et al. (1988) and in breast cancer demonstrated by Bouzubar 
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et al. (1989). Ki67 was believed to be a good predictor of metastases and recurrence and 
was proven in many studies to be correlated with higher tumour grades as suggested by 
WHO 2010  (Erler et al., 2011). 
In GEPNET, Ki67 has a very significant prognostic value (Foltyn et al., 2012) 
and was proven to be a reliable and reproducible marker by Salama et al. (2014) 
 
2.3 SURVIVIN 
2.3.1 Introduction to survivin 
 Predicting disease outcome is very important in understanding the natural history 
of tumours in general and specifically in GEPNET, planning treatment strategies and 
devising follow up plans. Many other prognostic markers are now being studied with the 
aim to discover a highly specific and sensitive marker to feed this purpose, apart from 
above mentioned Ki67. Studies done by Alexander et al. (2014) explored the usage of 
OCT 4 marker in neuroendocrine tumours in various sites and by Brunner et al. (2015) 
who experimented on E-cadherin, β-catenin, cyclin D1 and IL-17A. One potential marker 
exhibiting increasing interest in the diagnostic and prognostication in GEPNET is 
SURVIVIN. 
Survivin in a protein belonging to the family of inhibitor of apoptosis (IAP) family 
of molecules. XIAP, NAIP, c-IAP1,c-IAP2, livin , ILPP2 and BRUCE are all the other 
members in this family (Deveraux and Reed, 1999; Cheung et al., 2006). 
Apoptosis, is a physiological cell suicide programme while avoiding 
inflammation and damage to the surrounding tissue. This is a crucial entity in the 
development and maintenance of a healthy and normal tissue. Dysregulation or 
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malfunction of this programme can lead to initiation of  cancer, autoimmune and 
immunodeficiency disease, reperfusion injury after ischaemic episodes and in 
neurodegenerative disorders (Deveraux and Reed, 1999). 
 
2.3.2 Structure of survivin 
IAP was first discovered in baculoviruses, and was shown to be involved in 
suppressing cell death response to viral infection (Deveraux and Reed, 1999). IAP family 
protein are defined by a domain of 70 amino acids called baculovirus IAP repeat ( 
BIR).Up to three copies of this BIR domain can be present in IAP. Other sequences that 
can be found in certain IAP includes RING finger domain which is defined by 7 cystein 
and 1 histidine residues, a caspase recruitment domain ( CARD), an ubiquitin conjugative 
motif  and a nucleotide P-loop sequence (Deveraux and Reed, 1999) 
Survivin is the smallest protein in the IAP group, consisting of 142 amino acid 
residues and a molecular mass of 16.5 kDa. It  possesses a single BIR domain, and instead 
of having a RING finger domain, it is replaced by a  long amphipathic alpha-helical 
region as shown in Figure 2.1 (Verdecia, 2000). It suppresses apoptosis and regulates cell 
division (Altieri, 2008). 
X-ray crystallography revealed the structure of human survivin, in which there 
are presence of an amino-terminal globular zinc finger domain (which includes the BIR 
motif) and a long carboxy-terminal helix separated by a short linked segment, important 
for dimerization (Rodríguez et al., 2002) . This structure is closely related to its function 
as an apoptotic inhibitor. The amino terminal portion consists of 3 alpha helices and three 
beta sheets, which closely resembles the BIR domain that is conserved in the IAP family, 
which are crucially involved in their function in inhibiting apoptosis. 
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2.3.3 Biological function 
 
How does survivin inhibit apoptosis? In order to maintain a healthy tissue, there 
must be a balanced homeostasis between proliferation and cell death. The disruption of 
this balance by oncogenes are kept in check as strong proliferation stimulus also lead to 
the production of death signal. Caspases are a family of endoproteases. The activation of 
this enzymes in unfavourable cell environment can result in substrate inactivation and 
generate active signalling molecule to participate in apoptotic and inflammatory 
processes in maintaining the normal homeostasis. 
Guo and Hay (1999) suggested that caspase activity occurs during each cell cycle 
and survivin acts to halt this activity. Alternatively, it was also suggested that survivin 
and caspase activity work hand in hand as part of the G2/M checkpoint. In such model, 
*Adapted fromVerdecia (2000) 
Figure 2.1 : Survivin structure 
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survivin associated with microtubule is needed to block caspase activity during G2/M, in 
which disturbances to the microtubule will lead to a malfunction survivin and increase in 
death promoting activity. This finding was also similar to a study done by (Li and Altieri, 
1999) that shows that survivin is upregulated in G2/M and that it is associated with 
spindle microtubule and seems to require this association for antiapoptotic activity. 
Another implication of survivin apart from inhibition of apoptosis is its ability to 
enhance angiogenesis. Evidences linking survivin with angiogenesis include study done 
by 1) O'Connor et al. (2000) who demonstrated that survivin was upregulated in 
angiogenically stimulated endothelial cells compared to quiescent cells; 2) Tran et al. 
(2002), survivin expression was increased in cultures vascular endothelial cells following 
exposure to angiogenic factors such as VEGF and basic FGF; 3) Conway et al. (2003) 
found that following middle cerebral artery occlusion, mice with heterogenous deficiency 
of the survivin gene exhibited decreased blood vessels density. The mechanism by which 
survivin enhances angiogenesis and its ability to inhibit apoptosis will result in 
enhancement of cell survival. 
 
2.3.4 Survivin and Cancer 
IAP proteins have received a lot of attention in the last two decades, specifically 
in their ability to suppress apoptosis involving direct caspase inhibition. The 
identification of survivin as a structurally unique IAP protein and their role in cancer was 
brought to highlight with the fact that  this protein is expressed during fetal development 
and in human cancers but not in normal adult tissues in vivo (Ambosini, 1997). Early 
work using SAGE ( Serial analysis of gene expression ) ranked survivin as the fourth 
most highly expressed transcript in a number of common  cancers but rarely expressed in 
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normal tissue (Velculescu et al., 1999). This unique entity of being expressed at high 
levels during fetal development, but rarely in normal healthy adult tissue, makes survivin 
very attractive target for tumour marker, prognostic marker and an anti cancer therapy 
target.  
Multiple studies have been done to attest the potential of survivin as a tumour 
marker. Multiple studies were done to show that the expression of survivin was seen to 
be a good diagnostic potential in bladder tumour (Shariat et al., 2004; Schultz et al., 2006) 
where they were found positive in new and recurrent bladder cancer but not detected in  
patients who had undergone treatment and had negative cystoscopy findings (Smith et 
al., 2001). A significant positive correlation was found between survivin and colorectal 
cancer, with emphasize on survivin levels and microvessel density, proving its 
involvement in tumour through angiogenesis (Kawasaki et al., 2001). 
Prognostic markers predict patient outcome and does have a significant influence 
in cancer management. Traditional prognostic factors for cancer include parameters such 
as tumour size, tumour grade and local or distant lymph nodes metastases. The ability of 
survivin to inhibit apoptosis and enhance angiogenesis makes it a good prospect as a 
prognostic marker. Because survivin were known to be involved in these processes, it is 
highly likely to be involved in tumour progression and consequently in leading to a higher 
level in aggressive tumours. This fact was repeatedly seen in breast cancer studies done 
by Span et al. (2004) and Ryan et al. (2006). 
The association of survivin as a diagnostic and prognostic marker and GEPNET 
has also drawn an increasing interest. However, in comparison to other types of cancers, 
there were limited studies done to correlate both survivin and GEPNET. One study by 
Vikman (2005)  exhibited that genes for survivin showed more restricted expression in 
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normal tissue but were found to be robustly expressed in midgut neuroendocrine tumour. 
Another study by Patricia Grabowski (2005) showed that nuclear survivin is a powerful 
prognostic marker in GEPNET. 
Survivin is upregulated at G2/M phase of the cell cycle and downregulated at the 
G1 phase (Li et al., 2005) , making it more specific in comparison to Ki67 which is 
expressed in G1, S, G2 and M phases but not in G0 phase. Ki67 antigen is expressed in 
every phase of the cell cycle and if the cell cycle becomes prolonged by G1 or S arrest, 
more mitoses may be visible without necessarily reflecting an accelerated growth rate. It 
is also an emerging area of interest where there is a possibility of using this gene product 
as target antigen for anti-cancer therapy (Ryan et al., 2009) and T cell mediated therapy 
(Vikman, 2005). Because of the lack in studies correlating survivin and GEPNET and 
that survivin appears to be more specific than Ki67, we would like to explore more of the 
expression of survivin in our study. 
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CHAPTER THREE : AIMS AND OBJECTIVES 
 
3.1 GENERAL OBJECTIVES 
 
To observe the prevalence of Gastroentero-pancreatic Neuroendocrine Tumour 
(GEPNET) in HUSM in accordance to WHO 2010 classification with the added use of 
survivin as a prognostic tool 
 
3.2 SPECIFIC OBJECTIVES 
 
 To identify the prevalence of Gastroentero-pancreatic Neuroendocrine Tumour 
(GEPNET) in HUSM 
 To reclassify all cases diagnosed as Gastroentero-pancreatic Neuroendocrine 
Tumour (GEPNET) under the WHO 2010 classification 
 To determine the clinicopathological characteristics of Gastroentero-pancreatic 
Neuroendocrine Tumour (GEPNET) in HUSM 
 To determine the association of prognosis (Grade) with expression of survivin in 
Gastroentero-pancreatic Neuroendocrine Tumour (GEPNET) 
 
 
 
 
 
 
 
 
18 
 
3.3 RESEARCH QUESTION 
 
 What is the prevalence of Gastroentero-pancreatic Neuroendocrine Tumour                  
(GEPNET) in HUSM? 
 What are the clinicopathological presentations among those diagnosed with 
Gastroentero-pancreatic Neuroendocrine Tumour (GEP-NET)? 
 Is survivin being expressed in Gastroentero-pancreatic Neuroendocrine Tumour 
(GEPNET) and does it have a role in terms of prognostic value in Gastroentero-
pancreatic Neuroendocrine Tumour (GEPNET)? 
 
 
3.4 RESEARCH HYPOTHESES 
 
 H0 – There is no relationship between survivin expression with tumour grade  
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CHAPTER FOUR : METHODOLOGY 
4.1 STUDY DESIGN AND SAMPLES 
This study was a cross sectional (retrospective) study. All samples were retrieved 
from the archived paraffin-embedded tissue blocks diagnosed by independent 
pathologists in the Department of Pathology, Hospital Universiti Sains Malaysia (USM) 
between 1998 to 2016. Selection were based on the confirmed diagnosis of 
neuroendocrine tumour or carcinoid of the gastroenteropancreatic region based on 
histopathological findings. The inclusion of the terminology ‘carcinoid” was used as the 
term was still widely utilized in previous years. All cases were diagnosed based on 
morphology and available immunohistochemical markers that were available at that time. 
The demographic data and histopathological examination reports were obtained from the 
archived LIS (Lab Information System) and PATHORS system of Hospital Universiti 
Sains Malaysia, Kelantan.  
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4.2 SAMPLE SIZE 
Sample size for this study was calculated to fulfil the following objectives. 
 
OBJECTIVE 1 
To observe the prevalence of GEPNET in HUSM 
 SINGLE PROPORTION FORMULA 
o n =(z/∆)2 p (1-p) 
o n= sample size    z= z distribution = 1.96    Δ= precision (0.005 ) 
o P= 0.00035 prevalence of GEPNET based on previous study is 35/100000 
(Yao et al., 2008) 
o Absolute precision (∆) = ±0.005 (0.5%) 
o n = (1.96 / 0.005)2 (0.00035) (1- 0.00035)   
    = 53 
Sample required according to calculation : 53 patients 
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OBJECTIVE 2 AND  3 
To reclassify all cases diagnosed as GEPNET under the WHO 2010 classification 
To identify the clinicopathological characteristics of GEP NET in HUSM 
 
 SINGLE PROPORTION FORMULA (Gender-male) 
 
o N=(z/∆)2p(1-p) 
o n= sample size    z= z distribution = 1.96    Δ= precision (0.15) 
o P= 0.47  prevalence of male in GEPNET based on previous study is 47%  
(Gunavathy, 2014) 
o Absolute precision (∆) = ±0.15 (15%) 
o n = (1.96 / 0.15)2 (0.47)(1- 0.47)   
=42 
Sample required according to calculation: 42 patients 
 
 SINGLE PROPORTION FORMULA (Ethnicity) 
 
o N=(z/∆)2p(1-p) 
o n= sample size    z= z distribution = 1.96    Δ= precision (0.15) 
o P= 0.39  prevalence of Malay in GEPNET based on previous study is 39%  
(Gunavathy, 2014) 
o Absolute precision (∆) = ±0.15 (15%) 
o n = (1.96 / 0.15)2 (0.39)(1- 0.39)   
=40 
 Sample required according to calculation: 40 patients 
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 SINGLE PROPORTION FORMULA (Metastases) 
o N=(z/∆)2p(1-p) 
o n= sample size    z= z distribution = 1.96    Δ= precision (0.15) 
o P= 0.70  prevalence of metastases in GEPNET based on previous study is 
70%  (Singh et al., 2014 & Law, 2014) 
o Absolute precision (∆) = ±0.15 (15%) 
o n = (1.96 / 0.15)2 (0.70)(1- 0.70)   
=35 
 Sample required according to calculation: 35 patients 
 
OBJECTIVE  4 
To determine the association of expression of survivin with prognosis (grade) in 
GEPNET 
 
PS software ( 2 proportion formula)(Dupont and Plummer, 1997) 
o α= 0.05, Power = 0.8, p0 =?   , p1 =?    , m = 1 
o P0= 0.75 (proportion of patient with poorer grade who has negative survivin 
expression)  (Li et al., 2005 Javle, & Tan, 2005) 
o P1= 0.25 (proportion of patient with poorer grade who has positive survivin 
expression) 
o Sample size = 12 
o Sample size + 10% dropout= 14 
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4.3 INCLUSION CRITERIA 
 
 All patients diagnosed with gastroentero-pancreatic neuroendocrine tumour 
(GEPNET) or carcinoid of the gastroentero-pancreatic region based on histopathological 
and immunohistochemical marker findings. 
 
4.4 EXCLUSION CRITERIA 
 
Cases that fulfilled the inclusion criteria but were found to have missing 
corresponding blocks were excluded from the study. Other exclusion criteria include 
inadequate tumour tissue for serial section. Cases other than gastroenteropancreatic 
neuroendocrine or carcinoid tumour were also omitted. 
 
 
4.5 SAMPLING METHOD 
 
 Cases from 1998 to 2016 that fulfilled the inclusion criteria were retrieved form 
archived LIS ( Lab Information System) and PATHORS system of Hospital Universiti 
Sains Malaysia, Kelantan. Corresponding tissue blocks were then obtained from the 
tissue archive and cases were then excluded from the study based on the exclusion 
criteria. Sampling method cannot be applied in this study due to the limited number of 
cases. 
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4.6 TISSUE PROCESSING AND IMMUNOHISTOCHEMICAL STAINING. 
 
4.6.1 Primary Antibodies 
Primary antibodies are antibodies that are raised against an antigenic target of interest 
and are typically unconjugated (unlabelled). Primary antibodies that recognize and bind 
with high affinity and specificity to unique epitopes are available as high specificity 
monoclonal antibodies and/or polyclonal antibodies. This antibody can be very useful for 
the detection of biomarkers for diseases. Primary antibodies used in this study are as 
below: 
 
a) Ki67 
Ki 67 primary antibody that was used in this study is clone MIB-a, manufactured and 
marketed by Dako Denmark A/S. This antibody is a monoclonal antibody that is 
derived from a mouse. Human tonsil was used as positive control. 
 
b) Survivin (Al-Joudi, 2004) 
Survivin primary antibody was obtained and prepared in the research laboratory at 
the Chemical Pathology Department, Universiti Sains Malaysia. This was done by 
hyperimmunisation of rabbits with oligopeptides. These oligopeptides contain 
sequences that represent the C- and N-termini of the survivin amino acid sequence. 
The produced antibodies were tested for specificity by preabsorption test in 
competition ELISA and immunoblotting. These sera containing antibodies were 
tested and validated using colon cancer tissue and breast cancer tissue. 
 
